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 ABSTRACT (ENGLISH) 
Longitudinal bone growth is a complex process that takes place in the growth plate, and 
normal growth is dependent on a precise balance of several endocrine and paracrine factors. 
Growth impairment is common in children with inflammatory diseases and is associated with 
elevated levels of pro-inflammatory cytokines and long-term glucocorticoid treatment. To 
date, no treatments are available to treat growth impairment caused by glucocorticoids and 
there is a need to find new strategies to counteract the negative side effects of glucocorticoids 
on bone growth.  
The aim of this thesis was to study bone growth impairment induced by glucocorticoids and 
inflammation and the underlying molecular mechanisms. The aim was also to address 
whether the mitochondrial derived peptide humanin potentially could rescue from 
glucocorticoid-induced bone growth impairment and apoptosis in the growth plate, without 
interfering with the anti-inflammatory effect of glucocorticoids. 
In study I the effect of glucocorticoids and humanin on bone growth was assessed in several 
different experimental models. We discovered that the synthetic humanin analogue, HNG, 
completely rescued from dexamethasone-induced bone growth impairment and that humanin 
over-expressing mice were resistant to glucocorticoid-induced growth impairment. In 
addition, our results indicate that humanin is a novel regulator of Hedgehog signaling. 
In study II we assessed whether HNG could rescue from glucocorticoid-induced apoptosis in 
the growth plate in a model of chronic inflammation. We showed that HNG treatment 
suppressed apoptosis in both growth plate and articular cartilage. Importantly, we found that 
HNG did not interfere with the anti-inflammatory effect of dexamethasone. 
In study III we investigated the effect of dexamethasone on bone growth and chondrogenesis 
in a disease model of chronic inflammation. By using the transgenic TNF over-expressing 
mouse model (tgTNF) we found that chronic inflammation by itself suppressed bone growth 
and that dexamethasone treatment further suppressed bone growth despite its anti-
inflammatory actions. We also showed that Indian hedgehog and humanin expression levels 
were suppressed in the growth plate of the tgTNF mice, suggesting a new mechanism for 
inflammation induced growth impairment. 
 
  
ABSTRAKT (SVENSKA) 
Längdtillväxt är en komplex process som sker i tillväxtplattan. Brosket i tillväxplattan är 
uppbyggt av kondrocyter i olika stadier av differentiering. För att längdtillväxten skall ske på 
ett normalt sätt är dessa celler strikt reglerade av olika endokrina- och parakrina faktorer. 
Försämrad längdtillväxt ses ofta vid kroniska inflammatoriska sjukdomar där vanligt 
förekommande långvarig kortisonbehandling bidrar till den försämrade tillväxten. I dagsläget 
finns ingen effektiv behandling som kan motverka denna typ av tillväxthämning. Det finns 
därför ett behov av att utveckla nya metoder och läkemedel för att undvika de negativa 
bieffekterna som glukokortikoider och inflammation har på längdtillväxten. 
I avhandlingsarbetet har det övergripande målet varit att studera effekterna av 
glukokortikoiden dexametason på längdtillväxten och kondrogenesen i tillväxtplattan samt att 
studera den mitokondriella peptiden humanin och dess potential att förhindra 
tillväxthämmning till följd av glukokortikoidbehandling. Vi har även studerat en modell av 
kronisk inflammation där den proinflammatoriska cytokinen TNF är överuttryckt och 
längdtillväxten hämmad för att kartlägga hur behandling med en glukokortikoid påverkar 
tillväxten i denna sjukdomsmodell. 
I studie I har vi påvisat att humanin kan hindra glukokortikoid-inducerad tillväxthämmning i 
växande normala möss. Vi såg även att längdtillväxten och kondrogenesen i humanin-
överuttryckande möss inte påverkades negativt av dexametasonbehandling. Våra resultat 
visar att humanin reglerar Hedgehog-signaleringskaskaden vilket kan vara en ny mekanism 
för hur humanin verkar på kondrocyterna i tillväxtplattan. 
I studie II har vi påvisat att humanin hämmar apoptos i tillväxtplattan som uppstår till följd 
av glukokortikoidbehandling i en djurmodell med kronisk inflammation. I denna studie 
visade vi även att humanin i kombination med dexametason inte påverkar den anti-
inflammatoriska effekten. 
I studie III har vi påvisat att längdtillväxten hämmas i möss med överuttryck av cytokinen 
TNF och att dexametason, trots dess anti-inflammatoriska effekt, ytterligare hämmar 
tillväxten i dessa möss. Vi såg även att uttrycket av Indian hedgehog och humanin i 
tillväxtplattan var nedreglerat  i möss med överttryck av TNF vilket kan ge insikt i en ny 
molekylär mekanism för hur tillväxthämning uppstår till följd av kronisk inflammation.   
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1 INTRODUCTION 
1.1 LONGITUDINAL BONE GROWTH  
Longitudinal bone growth is a complex series of events highly dependent on the proper 
balance between several crucial factors including hormones, growth factors and nutrition, 
which all influence the final height of an individual. The growth potential is genetically 
determined but environmental factors, poor psychosocial situation, and a variety of chronic 
diseases may also influence the bone growth and may result in short stature if not treated. 
Therefore, bone growth in general is a very good indicator of good health. 
Postnatal longitudinal bone growth in humans can be divided into three phases; infancy, 
childhood and pubertal according to the ICP-model established by Karlberg in 1989 [1]. 
During infancy and childhood, longitudinal bone growth is stimulated to a large extent by 
growth hormone (GH) and nutrition while sex steroids are the main stimulators of growth 
during puberty. At the end of puberty, sex steroids stimulate growth plate closure and final 
adult height is achieved [2]. 
1.1.1 Growth plate structure  
Longitudinal bone growth is a result of a mechanism called endochondral ossification, where 
bone is formed after a cartilaginous template has been generated. This process occurs at the 
growth plate, a thin layer of cartilage situated at both ends between the diaphysis and the 
epiphysis of all long bones [3]. The growth plate consists of chondrocytes at different levels 
of differentiation, distributed within three distinct zones; the resting, proliferative and 
hypertrophic zone [4] (Figure 1).  
The chondrocytes within these three zones have different characteristics. Chondrocytes in the 
resting zone are not very active metabolically, but these stem-like cells serve as an important 
reservoir for the growth plate and studies have shown that the resting zone alone can give rise 
to the entire growth plate [5]. When they divide they give rise to daughter cell columns in the 
proliferative zone. The chondrocytes of the proliferative zone, on the other hand, proliferate 
actively and play a major role in the matrix production. These cells are larger in size and form 
columns parallel to the long axis of the bone. Further maturation of these chondrocytes leads 
to hypertrophy. Chondrocytes in the hypertrophic zone increase in size and produce collagen 
type X, alkaline phosphatase and matrix metalloproteinases. Later, the terminally 
differentiated chondrocytes die by apoptosis and the growth plate is invaded by blood vessels 
and bone cell precursors, which gradually remodel the hypertrophic zone cartilage into bone 
[4]. 
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Longitudinal bone growth is therefore a result of proliferation, enlargement of hypertrophic 
chondrocytes and production of extracellular matrix proteins in the proliferative and 
hypertrophic zones. 
 
 
 
1.1.2 Regulation of longitudinal bone growth 
Hormones are the major regulators in the process of longitudinal bone growth and most 
central and most studied is the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis 
together with thyroid hormones and sex steroids [6]. Several local factors are also involved in 
the regulation of bone growth, including the Indian Hedgehog (Ihh) and parathyroid 
hormone-related peptide (PTHrP) signaling as well as bone morphogenic proteins, fibroblast 
growth factors and vascular endothelial growth factors. How these hormonal and local factors 
interact with each other to regulate bone growth is still unclear.  
1.1.2.1 GH/IGF-1 axis 
GH is a peptide hormone secreted by the pituitary gland and is mainly promoted by GH-
releasing hormone (GHRH) and inhibited by somatostatin from the hypothalamus. GH is 
known to stimulate bone growth indirectly by affecting circulating IGF-1 levels but also by 
stimulating local production of IGF-1 in the growth plate [2]. However, according to the 
original “somatomedin hypothesis”, GH (somatomedin) only has indirect effects on bone 
growth by stimulating the production of IGF-1 in the liver [7]. Later, this hypothesis was 
Figure 1. Structure of the growth plate cartilage. The growth plate is located in 
each end of the long bones and is divided into three distinct zones; the resting, 
proliferative and hypertrophic zone. 
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modified because new findings showed that GH also has direct effects on longitudinal bone 
growth independent of IGF-1 [8-10]. 
The action of GH is mediated by its binding to the GH receptor (GHR), which is highly 
expressed in many tissues such as liver, heart, kidneys, pancreas, cartilage and skeletal 
muscle where it stimulates the synthesis of IGF-1 [11]. The GHR can also be detected in the 
chondrocytes of all zones of the growth plate, indicating that GH has a direct growth 
promoting effect in the growth plate [12]. Further evidence for direct actions of GH has been 
shown in studies where local GH injection into the tibia growth plate of rats accelerated bone 
growth compared to the untreated unilateral bone [9]. GH is capable of stimulating 
proliferation by direct action on the resting chondrocytes in the growth plate [13]. 
The local action of GH involves recruitment of resting chondrocytes into the proliferative 
state and stimulation of local IGF-1 production, which stimulates proliferation of proliferative 
chondrocytes. Suppressor of cytokine signaling (SOCS) 2 has been suggested to locally 
regulate GH in the growth plate as SOCS2 knockout mice display an overgrowth that is 
associated with increased GH/IGF-1 signaling. In addition, local GH signaling is increased in 
chondrocytes and metatarsals from SOCS2 knockout mice [14,15]. 
IGF-1 is essential for bone growth during both embryonic and postnatal life; whereas null 
mutation in the IGF-1 gene is associated with severe growth retardation [16]. However, liver-
specific IGF-1-deficient mice (LID) display normal bone length and body size despite a 25% 
reduction in circulating IGF-1 [17]. IGF-1, IGF-2 and IGF-binding protein 2 (IGFBP-2) have 
all been shown to be expressed in the growth plate of pre-pubertal mice, predominantly in the 
proliferative and pre-hypertrophic zones [18]. Patients with Laron syndrome have very low 
levels of circulating IGF-1 as a result of mutations in the GH receptor and abnormal GH 
signaling. These patients display extreme short stature and osteoporosis [19]. Similarly, bone 
growth is severely suppressed in IGF-1 and IGF-1R knock-out supporting the fact that IGF-1 
is essential for normal regulation of bone growth [20]. 
1.1.2.2 Ihh/PTHrP signaling 
The Hedgehog (Hh) signaling pathway is known to play a key role in bone growth regulation 
[21]. Among the three Hh ligands; Sonic (Shh), Indian (Ihh), and Desert (Dhh), only Shh and 
Ihh contribute to growth plate function. The Ihh ligand is expressed and secreted by pre-
hypertrophic and early hypertrophic cells in the growth plate [22]. Binding of Ihh to its 
receptor Patched-1 (Ptc-1) releases the membrane protein Smoothend (Smo), which activates 
the Hh signaling pathway and allows the activated transcription factor Gli to enter the nucleus 
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and enhance the transcription level of downstream target genes [22]. Recently, it has been 
proposed that Ihh signaling actually takes place in the primary cilia, sensory organelles 
protruding from the cell surface, which are important for mechano-biological signal 
transduction in chondrocytes [23]. 
Knock-out studies have reported that about 50% of Ihh-null embryos die early in 
development and those who developed to term die at birth, displaying abnormal chondrocyte 
proliferation and absence of mature osteoblasts [24]. Furthermore, studies have shown that 
Ihh over-expression alone is sufficient to increase chondrocyte proliferation [25]. Recent 
studies have reported that the Ihh inhibitor Vismodegib, which is used in the treatment of 
medulloblastoma, causes early growth plate fusion and growth impairment in treated children 
[26]. Vismodegib inhibit Hh signaling via Smo by suppressing Gli1 [27,28]. Altogether, these 
findings confirm the important role of Ihh in the growth plate and its regulation.  
1.2 BONE GROWTH IMPAIRMENT 
Short stature is generally defined as a standing height more than 2 standard deviations below 
the population mean (or below the 2.5
th
 percentile) for each sex. Many factors act 
individually or in combination to suppress bone growth by direct actions on the growth plate 
or indirectly by altering the GH/IGF-1 axis. In this thesis, the main focus has been on the 
impact of glucocorticoids (GCs) and inflammation on longitudinal bone growth and these 
factors will be described in more detail below. Figure 3 illustrates some of the important 
factors involved in the growth impairment frequently observed in children with chronic 
inflammatory diseases. 
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1.3 GLUCOCORTICOIDS AND BONE GROWTH 
1.3.1 Endogenous glucocorticoids 
Endogenous GCs are produced in the adrenal cortex and belong to the group of lipophilic 
steroid hormones that play a key role in lipid metabolism and adaptation to stress. Cortisol is 
the endogenously produced GC in humans and its synthesis and release is regulated by the 
hypothalamic-pituitary-adrenal (HPA) axis.  Environmental and physiological stress triggers 
the release of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) by the 
hypothalamus. CRH stimulates the synthesis and secretion of adrenocorticotropic hormone 
(ACTH) in the anterior pituitary gland which in turn stimulate the production of GCs in the 
adrenal cortex [29]. Feedback mechanisms ensure a tight control on the cortisol production 
and release. 
Because of their lipophilic structure, GCs can freely diffuse through the cell membrane and 
enter the cell. GCs bind to the glucocorticoid receptor (GR), which in its unbound and 
inactive form, resides in the cytosol in a complex containing heat shock protein 90 and 70, 
and other factors that enhance GRs affinity for its ligand. When GCs bind to the GR, it 
undergoes conformational change, which in turn leads to dissociation from the protein 
Figure 2. Several factors are contributing to growth impairment in conditions of chronic inflammation. 
Source: Reprinted with permission from BioScientifica Limited. Sederquist et al. Recent research on 
the growth plate: Impact of inflammatory cytokines on longitudinal bone growth. J Mol Endocrinol 
(2014) 53(1): T35-T44.  
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complex and translocation to the nucleus. In the nucleus GR interacts with DNA by binding 
to glucocorticoid response elements (GRE) and eventually activating (transactivation) or 
repressing (transrepression) specific sets of immune genes [30]. These genes code for 
cytokines, chemokines, inflammatory enzymes and receptors, and adhesion molecules that 
play a role in migration of cells towards sites of inflammation. Additionally, the GRs are 
capable of directly binding to specific transcription factors such as nuclear factor kappa light-
chain-enhancer of activated B cells (NF-κB). 
These genomic actions of GCs are considered to be the classical GC signaling pathway; 
however, it has been shown that GCs in addition have non-genomic actions independent on 
DNA interaction. These effects are rapid and are only observed following high-dose GC 
treatment [31]. Studies have revealed that GCs bind to membrane bound receptors which act 
through second messenger signaling, for example Ca
2+ 
and cAMP, which in turn activates 
different protein kinase pathways [32]. 
1.3.2 Glucocorticoid treatment 
Hench and colleagues were the first ones to introduce GCs to clinical practice in 1949 and 
these potent anti-inflammatory agents have been widely used ever since [33]. GCs such as 
dexamethasone (Dexa) and prednisolone are commonly used due to their high therapeutic 
efficacy as anti-inflammatory or immunosuppressant agents. However, long-term GC 
treatment is associated with severe side-effects including osteoporosis and bone growth 
impairment [34]. There are also individual differences in GC sensitivity which may be due to 
genetic factors. 
GC-induced growth impairment in children may be due to a combination of several factors 
and the degree of growth failure seems to be influenced by the duration of therapy, dosing 
and the specific agent. Nevertheless, clinical studies clearly show that longitudinal bone 
growth is negatively affected by GC treatment in children with chronic inflammatory diseases 
like juvenile idiopathic arthritis (JIA) and asthma [35]. Furthermore, a new study reports that 
early GC withdrawal improves long-term longitudinal bone growth and bone mineral density 
in children with renal transplantation, emphasizing the adverse effects of GCs on bone health 
in different conditions [36]. The growth suppressing effects of GCs are complex and 
multifactorial and currently, the underlying mechanisms of the growth suppressing effects of 
GCs are not fully understood. However, GCs are known to suppress bone growth through 
both systemic and local mechanisms.  
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1.3.3 Systemic growth suppressive effects of glucocorticoids 
Levels of circulating endogenous GCs are known to increase significantly during early onset 
of inflammation [37]. By inhibiting GH secretion and suppressing GH receptors in the liver, 
GCs indirectly inhibit IGF-1 production, resulting in impaired bone growth [38-40]. IGF-1 
levels have been shown to be decreased after short-term GC treatment, an effect which 
contributes to the GC-induced growth retardation in pre-pubertal mice [18]. 
1.3.4 Local growth suppressive effects of glucocorticoids 
Evidence of direct action of GCs on the growth plate was reported by Baron et al. in a study 
where local injection of Dexa suppressed tibia length compared to the contralateral untreated 
bone [41]. GCs directly target the growth plate cartilage by inhibiting chondrocyte 
proliferation and mineralization as well as increasing apoptosis [41-43]. Dexa and IGF-1 have 
opposite effects, where Dexa suppresses proliferation and IGF-1 stimulates proliferation of 
growth plate chondrocytes. Interestingly, it has been shown that the number of GCR decrease 
in the growth plate after some time of GC treatment, making the chondrocytes less sensitive 
to GCs [43]. 
Studies in young growing rats show that treatment with high dose GC induces undesired cell 
death in growth plate chondrocytes resulting in growth retardation [44]. The observed GC-
induced apoptosis was found to be regulated by activation of the caspase cascade, including 
caspase-8 and 9 as well as suppression of the Akt-phosphatidylinositol 3-kinase (PI3K) 
signaling pathway [45-48]. Additionally, GC treatment has been reported to regulate the Bcl-
2 family proteins such as Bcl-2 associated X protein (Bax), BH3 interacting-domain death 
agonist (Bid) and Bcl-2 homologous antagonist/killer (Bak) to activate apoptosis in 
proliferative chondrocytes [47]. Interestingly, young mice lacking the pro-apoptotic protein 
Bax are resistant to GC-induced bone growth impairment, suggesting an important role for 
the apoptotic machinery in the regulation of longitudinal bone growth and chondrogenesis 
[48]. A new study reports that fibroblast growth factor 23 (FGF23), which is involved in the 
regulation of phosphate homeostasis and bone growth, is upregulated in bone and plasma 
upon GC exposure [36]. Elevated FGF23 plasma levels are known to cause phosphate 
wasting, growth retardation, and impaired bone mineralization [49]. These results therefore 
suggest a novel mechanism which is partly responsible for the GC-induced growth 
suppression observed in pediatric kidney transplantation patients treated with GCs.  
The growth pattern known as catch-up growth is defined as the acceleration in growth in 
response to recovery from a disease or starvation and was first described by Prader et al. in 
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1963 [50]. Partial catch-up growth has been reported in children after withdrawal of GC 
treatment [51,52]. Similar results were also obtained in a study with postnatal rat metatarsal 
bones where partial catch-up growth was demonstrated after GC withdrawal [53]. However, a 
study in patients with cystic fibrosis reported permanent growth impairment due to GC 
treatment, suggesting a dose- and duration-dependent window for catch-up growth to occur 
[52]. Despite these clinical observations, the molecular mechanisms for catch-up growth are 
still poorly understood. 
1.4 INFLAMMATION AND BONE GROWTH 
Chronic inflammatory disorders like juvenile idiopathic arthritis (JIA), Crohn’s disease (CD) 
and ulcerative colitis (UC) are usually accompanied with growth retardation in young 
children. Several factors, such as pro-inflammatory cytokines, GC therapy and malnutrition, 
act individually or in combination and contribute to the growth retardation frequently 
observed in these children. Since they are acting both through systemic and local effects, it is 
difficult to distinguish if one factor is more significant than the other [54].  
Nutrition is an important regulator of bone growth where malnutrition is associated with 
chronic inflammation. The importance of proper nutritional status has been confirmed by 
studies in mice where food restriction resulted in deceased IGF-1 levels and suppressed GH 
receptor expression in the growth plate [55,56]. Malnutrition does contribute to growth 
retardation as shown in rat models of colitis, but only to about 60%, where the remaining 
growth impairment is due to the inflammatory condition itself [57]. The contribution of 
inflammation to growth impairment is further implicated in chronic inflammatory conditions 
such as JIA, where growth retardation has been reported historically, before GCs were 
commonly used as treatment as well as in JIA patients never treated with GCs [58,59]. These 
findings indicate that other factors than GC treatment contributes to the growth retardation 
seen in children with chronic inflammatory conditions.  
1.4.1 Systemic growth suppressive effect of cytokines 
Elevated levels of pro-inflammatory cytokines in conditions of chronic inflammation are 
known to act both individually and in combination to cause bone growth impairment [60]. 
Cytokines like TNF, IL-1β and IL-6 are secreted signaling molecules and are the most 
abundant cytokines up-regulated in inflammatory conditions like JIA [60].   
I has been reported that the pro-inflammatory cytokines TNF, IL-1β and IL-6 reduce the 
effect of IGF-1 in growth plate chondrocytes, an effect which was linked to reduced 
phosphorylation of signaling molecules of the PI3K  and MAPK/ERK1/2 signaling pathways 
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[61]. Furthermore, in vivo studies in transgenic mice overexpressing TNF or IL-6 both show 
growth retardation confirming the systemic growth suppressive effects of cytokines [62,63]. 
The IL-6 overexpressing mice display a growth reduction of 50-70% compared to non-
transgenic littermates, an effect associated with decreases in IGF-1 and IGFBP-1 levels [62]. 
Similar findings have been reported in patients with JIA as elevated levels of IL-6 negatively 
affect the levels of IGF-1 and IGFBP-3 [64]. 
1.4.2 Local growth suppressing effects of cytokines 
To date, there have not been many reports about the effects of pro-inflammatory cytokines in 
the growth plate. Best described are TNF, IL-1β and IL-6, which have shown varying effects 
on the growth plate chondrocytes. 
Mårtensson et al. reported that TNF can suppress longitudinal bone growth by directly 
targeting the growth plate cartilage in a model of cultured fetal rat metatarsal bones [65]. 
When metatarsal bones were exposed to a high concentration of TNF, they grew significantly 
slower compared to control bones. The observed growth suppression was associated with 
decreased chondrocyte proliferation and hypertrophy as well as increased apoptosis. Similar 
findings have been reported by others in the ATDC5 chondrocyte cell line where TNF was 
found to reduce mRNA expression of aggrecan, collagen II and collagen X, further 
emphasizing its negative impact on the growth plate cartilage [66].  
It has been reported that TNF is endogenously produced throughout the growth plate and 
plays a role in the normal regulation of longitudinal bone growth. Interestingly, treatment 
with etanercept, a soluble TNF receptor, improved bone growth as seen in  cultured fetal rat 
metatarsal bones [67]. These results indicate that the negative growth suppressive effects of 
TNF only occur at very high concentrations. 
Mice overexpressing TNF have been reported to have decreased total body length [63,68], 
decreased bone formation as well as numbers of osteoblasts [69]. Similarly, studies in the 
human TNF-overexpressing transgenic mouse line 197 (tgTNF) showed decreased trabecular 
bone in vertebrae and mice were susceptible to develop spontaneous disc herniation [70]. 
Similarly to the effects of TNF, IL-1β has been reported to suppress longitudinal bone growth 
in cultured fetal rat metatarsal bones by direct action on the growth plate [71]. The growth 
suppressive effect was associated with decreased chondrocyte proliferation, hypertrophy, and 
increased apoptosis and treatment with the IL-1 antagonist, anakinra, improved longitudinal 
bone growth [72]. However, unlike TNF and IL-1β, IL-6 did not have any effect on growth 
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plate chondrocytes or bone growth in the experimental model of metatarsal bones [71]. Later 
studies in ATDC5 chondrocytes showed, however, that IL-6 inhibits differentiation and 
decrease the expression of type II collagen, aggrecan, and type X collagen. In addition, 
another study in fetal rat metatarsal bones reported growth suppression when treated with IL-
6 in combination with its soluble receptor IL-6 Rα, suggesting a direct effect on the growth 
plate chondrocytes [73]. 
1.5 GROWTH PROMOTING THERAPIES  
GH is the main therapeutic approach to treat patients with short stature and has been used in 
the clinic since 1985, when synthetic GH was first produced [74]. Treatment of GC-induced 
growth impairment with GH has proved to increase linear bone growth [75,76]. However, at 
higher doses of GCs GH treatment was insufficient [77]. GH treatment in children with 
severe JIA improved height velocity and lean body mass indicating that GH could be a 
potential treatment to improve growth in these patients [75]. Another study reported that GH 
treatment is the most efficient in JIA patients with moderate disease activity [76]. However, 
the long-term safety of GH treatment has been questioned and it has not been approved as a 
treatment for GC-induced growth impairment. Therefore new strategies are needed to treat 
growth impairment induced by GCs. 
The introduction of anti-TNF therapeutics has revolutionized the management of 
autoimmune diseases and is an alternative to GC treatment with less adverse effects on bone 
growth and bone mineral density [78]. However, many patients do not respond to anti-TNF 
and require other forms of treatment to treat the primary disorder. Etanercept is a recombinant 
fusion protein that binds to TNF and inhibits its interaction with TNF receptors on the cell 
surface, thereby diminishing TNF-driven inflammation that plays a key role in many arthritis 
patients [78]. Due to the anti-inflammatory effect as well as decreased exposure to GC 
treatment, patients with JIA have proved to improved bone growth after initiation of 
etanercept [79]. 
Current challenges with GC treatment include the well-known adverse effects on bone 
growth and bone metabolism. Efforts have been made to minimize as many as possible of 
these side effects by optimizing GR-associated beneficial effects. A new class of 
pharmacological compounds such as GR agonists and modulators (SEGRAMs) has been 
intensively investigated during the past years [80]. AL-438 is an example of a non-steroidal 
GR ligand which shows reduced adverse effects on osteoblasts and bone growth but full anti-
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inflammatory effect in vitro [81]. More studies are needed to clarify the anti-inflammatory 
potential for these new compounds in vivo and whether they affect longitudinal bone growth. 
1.5.1 Mitochondrial derived peptides 
Mitochondrial derived peptides (MDPs) belong to a group of highly interesting, newly found 
signaling molecules that have turned out to be actively involved in the regulation of 
biological processes such as metabolism. The MDPs are encoded from short open reading 
frame (sORF) within the mitochondrial genome and after the discovery of the first MPD, 
humanin, the interest in this new class of molecules have increased and their positive effects 
have been studied in many different fields. Recently, another mitochondrial peptide, MOTS-c 
peptide (mitochondrial open reading frame of the 12S rRNA-c), was discovered and it has 
been shown to reduce obesity and insulin resistance in treated mice [82]. Six additional 
peptides have also been identified in the same region as humanin and were named small 
humanin like peptides (SHLPs). Out of these six peptides SHLP2 and SHLP3 in particular, 
seem to have similar protective and anti-apoptotic effects as humanin [83]. Thus, 
mitochondria play a critical role in metabolism by producing potent mitochondrial peptides 
and opens up a new field of research and possibilities to discover new drug targets. 
In this thesis we have payed particular attention to humanin and it will be described in more 
detail below. 
1.5.1.1 Humanin 
Humanin is a 24-amino acid peptide, encoded within the ORF of the 16S ribosomal RNA of 
the mitochondrial genome. The peptide was first identified in 2001 when isolated from a 
cDNA library of surviving neurons from an Alzheimer disease patient, and was described as 
a potent neurosurvival factor protecting neurons against amyloid-beta toxicity [84,85]. 
Simultaneously, the synthetic humanin analogue, humanin-Gly14 (HNG), was identified. In 
HNG, serine is replaced with glycine at position 14 in the amino-acid sequence and this 
analogue showed to be 1000 times more potent that the original peptide [84-86]. HNG has 
been shown to have a promising therapeutic potential in Alzheimer disease [85], diabetes 
[87], myocardial ischemia [88] and stroke [89]. Even though humanin has shown promising 
therapeutic effect in several different conditions, this has so far only been confirmed in 
experimental models and not in humans.  
Humanin is both an intracellular and secreted protein, which is thought to act trough binding 
to different cell surface receptors leading to initiation of intracellular signaling cascades 
eventually providing cytoprotection [90]. The identified receptors and associated signaling 
 12 
 
cascades are illustrated in Figure 4. Humanin was first found to bind to formylpeptide 
receptor-like-1 (FPRL1), a seven-transmembrane G-protein-coupled receptor [91]. This 
subsequently activates the downstream signaling pathway of ERK1/2. Later, humanin was 
also found to bind to a trimeric receptor consisting of ciliary neurotrophic factor receptor 
(CNTFR), the cytokine receptor WSX-1, and the transmembrane glycoprotein gp130 
(CNTFR/WSX-1/gp130) [92]. By binding to the gp130 receptor, humanin is capable to 
activate the canonical downstream signaling cascades of STAT3, Akt and ERK1/2 [93]. 
 
 
 
 
 
Humanin has shown anti-apoptotic effects both in vitro and in vivo. It can bind to IGFBP-3 
with high affinity and protect against IGFBP-3 induced apoptosis [94]. In addition, humanin 
has been reported to bind with the pro-apoptotic protein Bax and thereby prevent its 
translocation from cytosol to mitochondria and suppress cytochrome c release [95]. 
Figure 4. Interaction of humanin with different receptors and activation of downstream signaling 
pathways.  
Source: Reprinted with permission from Elsevier. Lee et al. Humanin: a harbinger of 
mitochondrial-derived peptides? Trends Endocrinol Metab (2014) 24(5): 222-8. 
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Furthermore, humanin is known to exert anti-inflammatory effects by suppressing cytokine 
levels such as TNF and IL-6 [92].  
Interestingly, GH-transgenic mice, characterized by displaying elevated levels of circulating 
GH and IGF-1, increased body size and reduction in lifespan [96], have been reported to have 
a 70% reduction of plasma humanin levels [97]. In contrast, Ames dwarf mice were reported 
to have a 40% increase in circulating humanin levels [97]. Similarly, an interesting study in 
patients with Laron syndrome, displaying extreme short stature and low levels of IGF-1, 
showed an 80% increase in plasma humanin levels compared to normal matched relatives 
[97]. These results clearly suggest that GH and IGF-1 are important regulators of humanin 
levels. Remarkably, humanin has been shown to exert an anti-cancer effect by itself by 
reducing the growth of cancer xenografts in SCID mice [98]. This finding may provide an 
explanation to the fact that patients with Laron syndrome, who have elevated levels of 
circulating humanin, have a decreased cancer risk. 
Humanin expression is age-dependent. Along with lower humanin levels in the 
hypothalamus, skeletal muscle, and cortex of older rodents, the circulating levels of humanin 
were found to decline with age in both humans and mice. These findings suggest that 
humanin plays a key role in the aging process [99].  
In this thesis, we have used HNG as well as humanin overexpressing mice (HNtg) to 
investigate the potential of this peptide to prevent GC-induced bone growth impairment.  
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2 AIM OF THE THESIS 
 
The overall aim of this thesis was, by different approaches, to study bone growth impairment 
induced by GCs and inflammation. 
The specific aims of the projects were: 
 To study the protective effects of  humanin on GC-induced bone growth impairment 
in different model systems in vitro and in vivo. 
 
 To study the potential for humanin to rescue from GC-induced apoptosis in the 
growth plate.  
 
 To investigate if HNG treatment interferes with the anti-inflammatory effect of GCs 
in an animal model of arthritis. 
 
 To study the effects of GCs and TNF on bone growth and chondrogenesis in an 
animal model of TNF overexpression. 
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3 MATERIALS AND METHODS 
The main model systems and methodologies used for this thesis are discussed in the 
following section. More detailed information about methodologies can be found in the 
separate papers. 
3.1 MODEL SYSTEMS 
There are several different models available to study longitudinal bone growth, and they all 
have advantages and drawbacks. However, it is crucial to choose the model that best suits the 
current investigation. It is also important to be aware of the differences between rodent 
models and humans when interpreting results. We have made an effort to choose in vitro 
models in order to minimize the use of animals. However, one disadvantage of the in vitro 
approach is that the observed responses may not reflect the complex interplay of systemic and 
local factors that are involved in vivo. 
3.1.1 Cell lines 
The human clonal chondrocytic cell line HCS-2/8 (chondrosarcoma-derived) was used for 
mechanistic studies to investigate Dexa-induced apoptosis and the potential for HNG to 
rescue from this effect (study I). The HCS-2/8 cell line is well characterized and widely used 
and has capacity to go through both proliferative and differentiated/hypertrophic phases. The 
RCJ3.1C5.18 rat chondrocytic cell line was also used to study Dexa-induced apoptosis (study 
II) and cultured as previously described [100]. 
Human macrophages were used to study if HNG may interfere with the desired anti-
inflammatory effect of Dexa. Briefly, mononuclear cells were isolated from healthy adult 
blood donors and re-suspended in 24-well tissue-culture plates in RPMI-1640 medium. 
Monocytes were separated by adhesion to tissue-culture plastic for 1 hour at 37 °C. Human 
monocyte-derived macrophages were then stimulated with 50 ng/ml macrophage colony-
stimulating factor (R&DSystems, Minneapolis, MN, USA) for additional 3 days in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. TNF levels in culture media 
were measured with ELISA. 
3.1.2 Organ cultures 
Fetal (embryonic day 20) rat metatarsal bones have been used to study the effects of different 
compounds on longitudinal bone growth [71]. The bones were dissected out and were 
thereafter cultured in serum-free medium that was changed every 2-3 days and cultured for 
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up to 12 days. Microscopic images were taken several times throughout the experiment 
allowing us to follow and measure bone growth. The increase in length is expressed as 
percent increase from day 0. 
3.1.3 Animal models 
All experimental procedures were performed with approval from the Stockholm North 
Ethical Committee in Sweden, University of Southern California in Los Angeles, CA, in the 
USA and the General Directorate of Rural Economy and Veterinary, region of Attica, in 
Greece. 
3.1.3.1 Normal mice 
In order to study longitudinal bone growth, young rapidly growing mice were used. To study 
GC-induced bone growth impairment, young FVB female mice were treated with Dexa (2 
mg/kg) and/or HNG (100 µg/kg), starting at 4 weeks of age and given by intraperitoneal (ip) 
or subcutaneous (sc) injection for 28 consecutive days. To exclude that the obtained results 
were strain- or sex related, C57BL/6 male mice were also treated with the same dose of Dexa.  
To mimic systemic inflammation, 4-week-old female C57BL/6 mice were challenged with 
lipopolysaccharide (LPS) (30 mg/kg). Animals received ip injections of HNG (100 μg/kg) 
and Dexa (2.5 mg/kg), 30 min before the injection of LPS. Three hours after injecting LPS, 
all mice were euthanized, blood was collected and serum IL-6 levels were measured. 
3.1.3.2 Humanin over-expressing transgenic mice 
Cytomegalovirus (CMV)-driven expression of humanin in C57BL/6 mice transgenic mice 
(HNtg) resulted into stable high expression of native humanin levels globally. A construct 
that includes the HN-ORF driven by a CMV promoter was injected into the pronucleus of 
fertilized B6D2F1 mice ova (Transgenic and Knockout Rodent Core Facility, USC, USA). 
Mice harboring the humanin transgene were viable and fertile. To obtain a congenic line, the 
transgene was backcrossed into the C57BL/6 strain. The overexpression of humanin was 
confirmed with ELISA.  
Four-week-old wild-type and HNtg male mice were treated with Dexa (2.5 mg/kg body 
weight/day, sc) or saline for 28 days. At the end point, plasma, femur and tibia were collected 
for further analysis.  
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3.1.3.3 Collagen-II induced arthritis 
The most commonly used animal model for rheumatoid arthritis is collagen-II induced 
arthritis (CIA). CIA in mice shares many features with the human rheumatoid arthritis, 
including symmetric joint involvement, synovitis as well as bone and cartilage destruction. 
Susceptibility to CIA in mice is associated with the expression of certain class II major 
histocompatibility molecules, which in mice is referred to as the H-2 complex. In mice, 
strains expressing H-2, such as DBA/1, are therefore highly susceptible to CIA [101]. In our 
study, we used DBA/1 female mice, with a weight of 18-20 g (approximately 8 weeks old). 
Under isoflurane anesthesia, mice were injected subcutaneously at the base of the tail with 
type II collagen (CII) prepared from bovine nasal cartilage emulsified in Freund’s complete 
adjuvant. Each mouse received 100 μg of CII and 300 μg of Mycobacterium tuberculosis in 
100 μL of emulsion. On day 28 after the first injection, the mice received a booster injection 
of 100 μg CII in 100 μL Freund’s incomplete adjuvant. Mice that did not develop any signs 
of arthritis within 14 days after the booster injection were excluded from the study. The study 
design is illustrated in Figure 5.  
 
 
 
 
3.1.3.4 Clinical evaluation of arthritis 
The mice were observed daily for the presence of arthritis including signs of erythema and 
swelling of the joints by a well-established protocol described previously (16). Briefly, the 
interphalangeal joints of the digits, the metacarpophalangeal joints and wrist in the forepaws 
Figure 5. Experimental design including time points of induction of 
CIA, treatment and number of animals included. 
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and the metatarsophalangeal joints and ankle joints in the hind-paws were each considered as 
one category of joints. Individual paws were scored on a scale of 0–3 as follows: 0 = no signs 
of arthritis, 1 = one type of joint affected, 2 = two types of joints affected, and 3 = the entire 
paw affected. Thus, the maximal score for each animal is 12, but mice reaching a total score 
of 9 were sacrificed due to ethical restrictions; therefore, score 9 represents the highest 
possible score allowed in this study. Clinical evaluation of arthritis was performed by three 
observers blinded to the identity of the animals. 
3.1.3.5  TNF transgenic models (tgTNF) 
The tg197 mouse stain, developed and described by Keffer et al., has been used in this thesis 
work [102]. Briefly, this animal model is characterized by over-expression of human TNF 
leading to the development of chronic, erosive and symmetrical polyarthritis resembling 
human rheumatoid arthritis. In the following text, we refer to this specific mouse strain as 
tgTNF. 
Starting from four weeks of age, the tgTNF animals received daily subcutaneous injections 
with Dexa (3 mg/kg) or saline for 4 consecutive weeks. After 4 weeks of treatment the 
animals were sacrificed by CO2, blood collected by heart punctuation and serum stored at -
80°C until analyzed. Hind limbs were dissected out for histopathological analysis. To assess 
longitudinal bone growth, femur length was measured by digital caliper after sacrifice. Femur 
from all animals were dissected and fixed in 4% formaldehyde for 24 hours followed by 
decalcification in EDTA buffer for 3–4 weeks before dehydration and paraffin embedding. 
Serial sections (5 μm thick) were stained with hematoxylin-eosin. 
3.1.4 Human growth plate biopsies 
We had the advantage of verifying our results obtained from cells and rodents in biopsies of 
intact human growth plate cartilages. The human tissue collection was approved by the local 
ethical committee (Stockholm North Ethical Committee, Sweden). According to this 
approval, informed consent was obtained from each subject and their parents, which was 
documented in the original hospital records. 
The biopsies were obtained from pubertal children (13-15 years old) undergoing epiphyseal 
surgery due to constitutional extreme tall statute or leg length difference. The growth plate 
cartilage from both femur and tibia was removed with a special biopsy needle and was 
immediately placed in sterile PBS on ice. Under sterile conditions, the biopsies were cut into 
thin slices under a microscope and were cultured in separate wells with serum-free medium 
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for 24 hours. The biopsies were then fixated with formaldehyde and decalcified with EDTA 
before being embedded in paraffin and sectioned for immunohistochemistry.  
3.2 ANALYSIS OF BONE GROWTH AND STRUCTURE 
3.2.1 X-ray 
X-ray has been used for analyzing longitudinal bone growth in mice. The mice were lightly 
anesthetized with isoflurane and X-ray images were taken once a week from the start of the 
experiment. The femur length was measured using computerized software (Sectra Image 
Display System 5). The total increase in percentage was calculated by dividing the length at 
time point 0 with the end point measurement. To measure longitudinal bone growth, femur 
X-ray images were captured before the start of treatment and thereafter every week 
throughout the study. 
3.2.2 Quantitative histology of the growth plate  
Growth plate histology was analyzed in femur sections stained with Alcian blue/van Gieson. 
Images were taken under light microscopy and further analyzed by the Image J software. 
Specifically, total growth plate area, total growth plate height and the height of the specific 
zones were analyzed. 
3.3 PROTEIN EXPRESSION 
3.3.1 Immunohistochemistry 
Immunohistochemistry was used for detecting and quantifying the expression of different 
proteins in formalin-fixed tissue sections of the growth plate. Briefly, this method utilizes 
specific antibodies to detect and localize target proteins in tissue sections. Detailed 
description of each protein can be found in the individual papers. 
Antibodies against the following proteins were used: Ihh, humanin, Bax, caspase-3, PCNA 
and collagen X. 
Sections were incubated with anti-caspase 3 antibody (sc-1226; Santa Cruz Biotechnology, 
Dallas, TX, USA), anti-proliferating cell nuclear antigen (PCNA) antibody (ab-18197; 
Abcam, Cambridge, United Kingdom), anti-humanin antibody (NB100-56877; Novus 
biologicals), anti-collagen X antibody (ab-58632 Abcam, Cambridge, United Kingdom) and 
anti-Ihh antibody (sc-1196; Santa Cruz Biotechnology). 
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Proliferating cell nuclear antigen (PCNA) is an intranuclear peptide which is a marker of cell 
proliferation and was used in our studies to assess proliferation in the growth plate. PCNA 
expression was analysed in serial sections of femur growth plates (n=5 bones per group) as 
described previously (17). Briefly, after deparaffinization and rehydration, antigen retrieval 
was performed in sodium citrate buffer (10 mM pH 6.0). The sections were blocked with 3% 
bovine serum albumin (BSA) before incubation overnight at 4°C with the primary rabbit anti-
PCNA antibody (1:100, Abcam 18197). Sections were incubated for 1 hour at RT with 
secondary goat anti-rabbit IgG-HRP antibody (1:300, Santa Cruz sc-2004) followed by 
incubation with an avidin-peroxidase complex (Vectastain ABC-kit PK-6100) and visualized 
with 3,3' diaminobenzidine (DAB) (Dako K3468) development for 3 minutes. Thereafter 
sections were counterstained with Alcian blue, dehydrated and coverslipped.  Images were 
captured by a Nikon Eclipse E800 light microscope connected to a digital camera 
(Hamamatsu C4742-95, Hamamatsu City, Japan) with a digital color camera system 
(Olympus DP70). Using the Image J software, the number of PCNA positive cells was 
determined by one observer blinded to the treatment. 
3.3.2 ELISA 
Circulating humanin was measured from wild-type control mice and HNtg mice plasma by an 
in-house sandwich ELISA, as previously described by Chin et al. [103]. Prior to assay, 
plasma was extracted with 90% acetonitrile and 10% 1N HCl. Briefly, 200 l of extraction 
reagent was added to 100 l of plasma, gently mixed and incubated at room temperature. The 
supernatant was removed and dried by SpeedVac after being centrifuged. The dried extracts 
were reconstituted with PBS and then used for ELISA. Synthetic HN was used as a standard 
within range 0.1 ng/ml to 50 ng/ml. 96-well microtiter plates were coated with capture 
antibody in 50 mM sodium bicarbonate buffer on a shaker. The plates were washed and 
blocked with Superblock buffer. Standards, controls or extracted samples and pretitered 
detection antibody were added to the appropriate wells and incubated overnight. The 
absorbance was read at 490 nm on a plate spectrophotometer followed by streptavidin-HRP 
and OPD steps. 
3.3.3 Western Blot 
Western immunoblotting was performed as described previously by us [47]. The primary 
antibodies against humanin C-14 (1:100), and Bax (1:1000), were from Santa Cruz 
Biotechnology. The antibody against Bid (P955957) was purchased from Cell signaling 
technology. To quantify Western blots Image J software was used. 
 23 
 
3.4 CELL DEATH ANALYSES 
3.4.1 TUNEL assay 
Apoptotic cell death by DNA fragmentation in chondrocytes in growth plate cartilage from 
humans and mice was studied by terminal deoxynucleotidyl transferase (TdT)-mediated 
biotinylated UTP nick end labeling (TUNEL). Serial sections of growth plate were stained 
with a TUNEL kit (EMD Millipore, Billerica, MA, USA and QIA33, TdT-FragEL, 
Calbiochem), according to the manufacturer’s instructions. Images covering the whole 
growth plate were analyzed under a fluorescence microscope (a Nikon E800 fitted with an 
Olympus DP70 camera). All TUNEL positive cells (Alexa-546, Invitrogen) were counted and 
divided by the total number of cells (DAPI stained) to achieve the percentage of TUNEL 
positive cells. For the digital cell counting, the Image J software was used.  
3.4.2 Analyses of histone-associated DNA fragmentation and mitochondrial 
potential 
To investigate cell death in cultured HCS-2/8 cells, cytoplasmic histone-associated DNA 
fragments (mono- and oligonucleasomes) were quantified using a Cell Death ELISA kit as 
previously described [45]. Mitochondrial membrane potential was measured in Dexa and 
HNG-treated chondrocytes as previously reported [48]. 
3.5 STATISTICAL ANALYSES 
Statistical significance of differences between two groups was evaluated by 2-tailed Student’s 
t test with 95% confidence intervals. For differences between several groups, parametric one-
way analysis of variance (ANOVA) was applied followed by Holm-Sidak test, or the non-
parametric Kruskal- Wallis ANOVA on Ranks followed by Dunn’s multiple comparison test. 
Statistical analysis of the clinical score in study II is based on area under the curve for each 
individual animal. The values are median clinical score and the error bars represent 
interquartile range. For the histological scoring, a mean value was calculated for each animal.  
All statistical analyses were performed using the SigmaPlot software (Systat Software Inc., 
IL, USA). All values are shown as means ± SD and ***p<0.001, **p<0.01 and *p<0.05 were 
considered statistically significant. 
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4 RESULTS AND DISCUSSION 
4.1 HUMANIN IS A NOVEL REGULATOR OF HEDGEHOG SIGNALING AND 
PREVENTS GLUCOCORTICOID-INDUCED BONE GROWTH IMPAIRMENT 
(PAPER I) 
 
Bone growth impairment in children is a common side effect of long-term and high-dose GC 
treatment and therefore it is desirable to find new treatment strategies to overcome this 
condition without interfering with the anti-inflammatory effect of GCs. In this study we 
sought to assess the potential for the mitochondrial derived peptide humanin, to rescue from 
Dexa-induced bone growth impairment without interfering with the anti-inflammatory effect. 
We also looked into the underlying molecular mechanisms and payed special attention to Hh-
signaling, an important regulator of bone growth.  
We could show that Dexa treatment in young wild-type mice significantly reduced bone 
growth whereas systemic administration of HNG treatment was able to rescue from this 
effect when administered in combination with Dexa. We had the advantage of studying the 
novel humanin over-expressing mouse model (HNtg) and we reported, for the first time, that 
HNtg mice treated with Dexa are resistant to Dexa-induced bone growth retardation (Figure 
6). 
Dexa treatment in wild-type mice was accompanied with suppression of total growth plate 
height and a decreased height of the resting + proliferative zone. HNG was able to restore this 
loss of growth plate height in Dexa treated wild-type mice. Interestingly, we observed that 
growth plate height was not affected by Dexa treatment in the HNtg mice. Mechanistic 
studies revealed that Dexa treatment suppressed chondrocyte proliferation in the growth 
plates of wild-type mice whereas co-treatment with HNG was able to rescue from this effect. 
Similar results were also obtained in cell cultures of chondrocytes and ex vivo cultured rat 
metatarsal bones.  In the HNtg mice, on the other hand, chondrocyte proliferation was not 
affected upon Dexa treatment. 
We further found that HNG suppressed GC-induced chondrocyte apoptosis in the growth 
plate both in vivo and in cultured fetal metatarsal bones. Similar results were obtained from 
experiments performed in cultured human growth plate cartilage, where Dexa treatment 
increased the apoptosis level but HNG was able to counteract this effect. Anti-apoptotic 
effects of humanin has previously been reported in different cell types, including pancreatic 
-cells, germ cells and neurons, but this is the first study to report anti-apoptotic effects of 
 26 
 
HNG in chondrocytes of human growth plate. We also showed for the first time that 
endogenous humanin is expressed in human growth plate cartilage (Figure 7). 
 
 
 
 
Previous studies have suggested that the anti-apoptotic effect of HNG is mediated through the 
binding of the pro-apoptotic protein Bax [95]. It has also been shown that GC-induced 
apoptosis in the growth plate is Bax-mediated and that Bax knock-out mice are resistant to 
GC-induced apoptosis [48]. Based on these findings we hypothesized that humanin may 
protect from GC-induced apoptosis in the growth plate. Indeed, in this study we found 
increased Bax expression in the growth plate upon Dexa treatment whereas HNG treatment 
was able to suppress Bax levels. This correlates well with the previous findings and 
strengthens the evidence for humanin to be a potent Bax-mediated inhibitor of apoptosis. 
We further found that Ihh expression was suppressed in the growth plates of Dexa treated 
wild-type mice and that HNG was capable of restoring Ihh levels in the growth plate. Hh-
signaling is known to be essential for chondrocyte proliferation and differentiation and 
Figure 6. Humanin prevents from GC-induced bone growth impairment in vivo. A) Schematic 
representation of experimental procedure. B) Longitudinal bone growth measured by weekly 
X-rays. C) Four week- old male wild-type and HNtg (C57BL6 background) mice were treated 
with/without Dexa (2.5 mg/kg body weight/d) for 28 consecutive days femur bone length was 
measured by digital caliper. 
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studies have reported that suppression of Ihh expression in chondrocytes cause growth plate 
fusion and impaired bone growth [26,104]. Ihh signaling has been proposed to take place in 
the primary cilia of the chondrocytes and the length of the primary cilium is proposed to 
modulate cilia function.  One example is that in the degenerative disease of osteoarthritis 
where increase in cilia length in articular chondrocytes is observed [105]. Elongation of the 
primary cilia in articular chondrocytes has also been reported upon LiCl treatment and was 
associated with inhibition of Hh signaling [106]. Interestingly, Dexa also seems to induce 
elongation of the primary cilia, however, this has so far not been studied in chondrocytes 
[107]. We further found that Dexa treatment in the HNtg mice did not suppress Ihh 
expression, suggesting that humanin promotes the survival of chondrocytes. This finding is 
highly interesting and provides a potential new mechanism for how humanin can prevent 
from bone growth impairment. Taken together, these findings suggest that the growth 
suppressive effects of Dexa may be due to suppression of Ihh signaling by affecting the size 
of the primary cilia. However, this needs to be clarified in future studies as well as the 
regulatory mechanisms for humanin. 
Importantly, we showed that HNG did not interfere with the anti-inflammatory effect of Dexa 
and that HNG by itself had an anti-inflammatory effect by lowering the levels of TNF and IL-
1β in mice with LPS-induced inflammation. These findings are in line with previous studies 
that have shown reduced levels of pro-inflammatory cytokines upon HNG treatment 
[108,109]. Although our study showed a direct action of HNG on the immune cells, the exact 
mechanism for how humanin exerts its anti-inflammatory effect is still unknown.  
In this study, we had the advantage of using several different model systems to test our 
hypothesis, which strengthens the results obtained. More specifically, we used the HNtg 
animal model in order to study the protective role of humanin on GC-induced bone growth 
impairment, and confirmed our findings in rodent tissues and in rare biopsies of human 
growth plate cartilage. 
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Figure 7. Humanin expression and protective effects of humanin in cultured human 
growth plate cartilage. A) Studies of endogenous humanin levels in human growth plate 
cartilage treated with Dexa (1 mM) for 24 hours shown in resting+proliferative zone 
and hypertrophic zone. B) Quantitative analysis of humanin expression (fold change). 
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4.2 HUMANIN PREVENTS UNDESIRED APOPTOSIS OF CHONDROCYTES 
WITHOUT INTERFERING WITH THE ANTI-INFLAMMATORY EFFECT OF 
DEXAMETHASONE IN COLLAGEN-INDUCED ARTHRITIS (PAPER II) 
 
There is a need for new treatment strategies to prevent bone growth impairment in children 
with chronic inflammatory disorders that are treated with GCs. In study I, we reported that 
humanin does not interfere with the anti-inflammatory effect of Dexa, using the LPS-induced 
inflammation model. In study II, we investigated if HNG can prevent GC-induced apoptosis 
in the growth plate in a disease model of chronic inflammation and, as a second step, if HNG 
may interfere with the anti-inflammatory effect of Dexa. To test our hypothesis, we used the 
well-established CIA model in DBA/1 mice, which is the most widely used mouse model of 
rheumatoid arthritis sharing many features with the human disease. 
From this study, we reported that HNG treatment suppressed GC-induced apoptosis in the 
growth plates of CIA mice (Figure 8). These findings were also verified in in vitro cultures of 
chondrocytes where HNG was able to suppress GC-induced apoptosis. These findings 
correlate well with our previous findings that HNG can protect from GC-induced apoptosis in 
the growth plate of healthy wild-type mice [110]. However, this is the first study to 
demonstrate the deleterious effect of Dexa on growth plate cartilage in a disease model with 
chronic inflammation. 
 
 
 
Figure 8. Effect of HNG on GC-induced apoptosis in femur growth plate and 
articular cartilage from CIA mice. Quantification of TUNEL positive cells in the 
growth plate and articular cartilage. 
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Importantly, we showed that HNG does not interfere with the anti-inflammatory effect of 
Dexa. These results are in line with our previous studies performed with normal mice where 
HNG protect from Dexa induced apoptosis in the growth plate. Interestingly, we observed a 
protective effect of HNG not only in the growth plate but also in the articular cartilage, which 
is a new area of research. 
Chronic inflammation, which results in up-regulation of pro-inflammatory cytokines, has a 
negative effect on the growth plate cartilage. However, it has not been clear to what extent 
GC treatment negatively affects chondrogenesis in the growth plate in a model of chronic 
inflammation as most studies have been performed in healthy wild-type mice. The CIA 
model of arthritis is well-characterized but to date, no studies have been performed on the 
growth plate cartilage. In this study, we were not able to examine longitudinal bone growth 
due to the age of mice at disease induction, which is one of the limiting factors of the study. 
At the time point for disease onset, the growth had reached a plateau and therefore this model 
was not suitable for analyzing bone growth. Interestingly, we show that Dexa treatment; 
despite effectively suppressing arthritis score and local inflammation, induced apoptosis in 
the growth plate chondrocytes. This suggests that Dexa may have growth suppressing effects 
in conditions of chronic inflammation but this needed to be clarified in another model 
allowing studies in younger animals. 
In previous studies by us and others, humanin has been reported to have anti-inflammatory 
effects both in vitro and in vivo [109,110]. In this study, we were not able to detect an anti-
inflammatory effect of humanin. The CIA mouse model displays acute and local 
inflammation and it is possible that the humanin dose used was too low to suppress 
inflammation. As humanin was administered systemically it is also possible that humanin 
was not able to penetrate into the joint and reach the location of the inflammation. Therefore, 
it would be important to study the effects of humanin in a different model of inflammation to 
verify the anti-inflammatory effects observed in earlier studies.  
In conclusion, this study showed evidence that GCs, in a model of chronic inflammation, 
induce apoptosis in the growth plate cartilage and humanin has the potential to rescue from 
this effect. These data adds to the understanding of how humanin can be used in combination 
with GC to protect from GC-induced bone growth impairment. 
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4.3 DEXAMETHASONE SUPPRESSES BONE GROWTH AND 
CHONDROGENESIS IN TNF OVER-EXPRESSING MICE (PAPER III) 
 
The reason for the observed growth impairment in young children is multifactorial but it is 
known that high levels of pro-inflammatory cytokines and long-term use of GCs are 
involved. The primary objective of study III was to elucidate the effect of Dexa on bone 
growth and chondrogenesis in a condition of chronic inflammation. To be able to address 
both bone growth and chronic inflammation, we used the human TNF over-expressing 
transgenic mouse model (tgTNF). Since tgTNF mice spontaneously develop chronic 
inflammation and arthritis at a young age this was a prerequisite for studying the longitudinal 
bone growth.  
Study III demonstrated that femur bone length and total growth plate height was significantly 
impaired in young tgTNF mice and that Dexa treatment, despite its anti-inflammatory effect, 
increased this negative effect (Figure 9). Our findings, with regard to the decreased bone 
growth, conform to other studies in the tgTNF mouse model where total body length was 
reported to be decreased [111] and bone formation reduced [69]. The additive growth 
suppressive effect of Dexa is a novel finding even though a similar effect has been shown in 
non-inflamed wild-type mice.  
The pro-inflammatory cytokine TNF, which is also called cachexin, is known to cause loss of 
appetite and a significant loss of body weight due to an altered metabolism [112]. In this 
study, we did not observe any loss of body weight in the tgTNF animals supporting the fact 
that the growth suppressing effects were most likely due to direct effects of TNF on the 
growth plate and not due to decreased food intake. 
The growth suppressing effect observed in the tgTNF mice was associated with increased 
apoptosis level and decreased chondrocyte hypertrophy in the growth plate. Dexa treatment 
did not further suppress chondrocyte proliferation or hypertrophy, nor did the treatment 
increase chondrocyte apoptosis in this animal model. It is well known that Dexa has 
deleterious effects on the growth plate cartilage and longitudinal bone growth by suppressing 
proliferation and hypertrophy of chondrocytes while increasing apoptosis in the growth plate 
of non-diseased wild-type mice [110].  Thus, our results suggest that Dexa treatment in the 
tgTNF mice, despite successfully reducing inflammation, is not capable of restoring 
chondrogenesis in these mice. 
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Interestingly, we observed that Ihh expression was significantly decreased in the growth plate 
cartilage of the tgTNF mice compared to wild-type mice. In a previous study by Tevlin et al. 
[113], elevated levels of TNF in diabetic mice directly suppressed Ihh expression in mouse 
skeletal stem cells, indicating a link between TNF and Ihh-signaling. These data suggest that 
TNF overexpression contributes to the suppression of Ihh expression in the growth plate, 
which may explain the impaired differentiation in the growth plates of tgTNF animals. 
Furthermore, we observed that circulating humanin levels as well as local humanin 
expression in the growth plate were suppressed in tgTNF mice when compared to wild-type 
mice. Suppression of humanin in the tgTNF model suggests that cytokines like TNF are 
capable of suppressing pro-survival signals which may then sensitize the chondrocytes to 
cellular toxicity. Furthermore, in study II, we showed that systemic treatment with the 
humanin analogue, HNG, blocked undesired apoptosis in the growth plate in wild-type mice 
with collagen-II induced arthritis [114]. Taken together, the data suggests that exogenous 
Figure 9. Femur bone length and total growth plate height in female wild-type (WT) and 
transgenic TNF-over expressing mice (tgTNF) treated with saline or Dexa (A-B). Femur 
bone length and total growth plate height in male and female tgTNF mice (C-D). 
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treatment with a potent humanin analogue could be a feasible strategy, not only to restore 
humanin levels in conditions of chronic inflammation, but also to prevent undesired 
inhibitory effects of Dexa and thereby prevent cellular toxicity and impaired chondrogenesis 
in the growth plate. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The underlying cause of growth suppression is complex and multifactorial. However growth 
retardation in children with chronic inflammation and GC treatment remains a clinical 
problem. The work in this thesis has focused particularly on the growth suppressive effects of 
GCs and inflammatory cytokines and how these effects potentially could be prevented by the 
mitochondrial peptide humanin. 
Specifically we have demonstrated that: 
 Systemic humanin treatment can protect from GC-induced bone growth impairment 
in young mice 
 
 Humanin over-expressing mice are resistant to GC-induced bone growth impairment  
 
 GC-induced bone growth impairment is associated with suppression of Ihh in growth 
plate chondrocytes and humanin treatment is able to restore the Ihh levels in wild-type 
mice 
 
 Humanin is expressed in the human growth plate and the expression level is 
decreased when the tissue is exposed to Dexa ex vivo 
 
 Humanin protects from GC-induced chondrocyte apoptosis in growth plates of mice 
with collagen-II induced arthritis 
 
 Humanin does not interfere with the anti-inflammatory effect of Dexa and has 
potentially an anti-inflammatory effect on its own 
 
 Femur bone growth and growth plate chondrogenesis are suppressed in TNF over-
expressing mice, effects that are even more pronounced under Dexa treatment 
 
 Expression levels of humanin and Ihh are suppressed in growth plates of TNF over-
expressing mice 
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The unwanted outcomes of GC treatment create a dilemma for clinicians because 
improvement in the primary inflammatory disease is achieved only by accepting substantial 
adverse effects that are often difficult to prevent or treat. Efforts have been made and 
different strategies have been implemented to prevent and treat GC-induced growth 
impairment in children. Recombinant human GH has been reported to improve growth in 
some children treated with GCs, although the effect is moderate and the cost high. However, 
it is important to emphasize that GH treatment has not been approved as a treatment for GC-
induced growth impairment. Anti-cytokine treatments have shown less adverse effects on 
bone growth and bone mineral density; however, many patients do not respond to the 
treatment.  
This thesis presents studies of a novel strategy to prevent GC-induced bone growth 
impairment, namely co-administration with humanin, a mitochondrial-derived peptide. Our 
data clearly show that humanin plays an important role in the growth plate cartilage. In 
combination with Dexa, humanin protects from GC-induced bone growth impairment which 
is associated with increased apoptosis and decreased proliferation. In study I, we report that 
humanin is a novel regulator of Hh signaling. Dexa treatment suppressed Ihh expression in 
the mouse growth plate and humanin was able to restore the expression levels. In the HNtg 
mouse model, Ihh expression was not affected upon Dexa treatment. These results are very 
interesting and indicate that humanin is involved in the regulation of Ihh; however, more 
studies are needed to clarify the exact underlying mechanisms. One possibility is that 
humanin interacts with the primary cilia, which has been reported to be the location for Ihh 
signaling in chondrocytes. Elongation of the primary cilia is associated with impairment in 
Ihh signaling and it would be important to investigate the possible links between humanin 
and structural changes of the primary cilia.   
Furthermore, we report that humanin does not interfere with the anti-inflammatory effect of 
Dexa, both in experiments with LPS induced inflammation (study I) and in a disease model 
of chronic inflammation (study II). These results suggest that a combination treatment with 
GC and humanin could provide a feasible approach to treat growth impairment. It is 
important to further investigate the anti-inflammatory effects of humanin applying different 
in vivo models of chronic inflammation. 
In study II, we observed that humanin was able to suppress GC-induced apoptosis not only in 
the growth plate but also in the articular cartilage. High doses of GCs, usually given as intra-
articular injections to treat arthritis, are known to have deleterious and toxic effect on the 
chondrocytes of the articular cartilage. Our results suggest that humanin treatment may have 
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the potential to rescue from this effect. However, further studies are needed to investigate the 
effect of humanin on articular cartilage and its potential to rescue from cartilage degradation. 
In addition to the adverse effects of GCs on chondrocytes, GCs are well known to have 
negative effects on osteoblasts resulting in osteoporosis in many of the treated patients. Based 
on our data, it can be speculated that humanin may also have protective effects on osteoblasts 
but this remains to be verified in future experimental studies. 
In study III, we found that serum humanin levels and the local growth plate expression of 
humanin were both decreased in the tgTNF mouse model. Altogether, our data suggest that 
inflammation with elevated TNF levels and GC treatment both suppress endogenous humanin 
making growth plate chondrocytes more sensitive to undergo apoptosis. Further in vivo 
studies are needed to clarify if humanin at different doses has the potential to rescue from 
growth impairment induced by chronic inflammation and concomitant GC treatment. 
In conclusion, our results confirmed both in vivo and in vitro, suggest that humanin has the 
potential to rescue from GC-induced bone growth impairment without interfering with the 
desired anti-inflammatory effect of GCs. Humanin act mainly by suppressing apoptosis but 
also by regulating Ihh expression at the growth plate level. Local humanin expression in the 
growth plate and circulating humanin levels were both decreased in the tgTNF mouse model 
suggesting that exogenous humanin treatment could potentially rescue the bone growth. Our 
findings, along with further advances in our understanding of the biology of bone growth, the 
pharmacology of GCs and mechanisms of humanin action, will hopefully lead to the 
development of new strategies to prevent growth impairment in children with chronic 
inflammatory disorders. 
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